Non-interventional post-authorization effectiveness study to assess long-term outcomes of Nintedanib treatment in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) (Nintedanib long-term outcomes in patients with SSc)

ENCePP Code of conduct

No

Data sources

• Data source(s), other:
  European Scleroderma Trials and Research (EUSTAR) registry Switzerland
• Data sources (types):
  Disease registry

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No